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Background: Data characterising long-term survivors (LTS) with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer (MBC) are limited. This analysis describes LTS using registHER observational study data.
Methods: A latent class modelling (LCM) approach was used to identify distinct homogenous patient groups (or classes) based on
progression-free survival (PFS), overall survival, and complete response. Demographics, clinicopathologic factors, first-line
treatment patterns, and clinical outcomes were described for each class. Class-associated factors were evaluated using logistic
regression analysis.
Results: LCM identified two survivor groups labelled as LTS (n¼ 244) and short-term survivors (STS; n¼ 757). Baseline
characteristics were similar between groups, although LTS were more likely to be white (83.6% vs 77.8%) with oestrogen receptor–
positive (ERþ ) or progesterone receptor–positive (PgRþ ) disease (59.4% vs 50.9%). Median PFS in LTS was 37.2 (95% confidence
interval (CI): 32.9–40.5) vs 7.3 months (95% CI: 6.8–8.0) in STS. Factors associated with long-term survival included ERþ or PgRþ
disease, metastasis to node/local sites, first-line trastuzumab use, and first-line taxane use.
Conclusions: Prognostic variables identified by LCM define a HER2-positive MBC patient profile and therapies that may be
associated with more favourable long-term outcomes, enabling treatment selection appropriate to the patient’s disease
characteristics.
Breast cancer is the leading cause of cancer-related death in
women, withB40 000 US women expected to die from this disease
in 2013 (Siegel et al, 2013). Amplification of the human epidermal
growth factor receptor 2 (HER2) gene occurs in approximately 20%
of patients with breast cancer (Ross et al, 2009; Dawood et al,
2010a), and this molecular subtype is associated with poor
prognostic factors as shown by its highly proliferative and often
high-grade histology (Eroles et al, 2012). In addition, patients with
HER2-positive disease are more likely to develop central nervous
system and visceral metastases than those with HER2-negative
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disease (Kallioniemi et al, 1991; Gabos et al, 2006; Pestalozzi et al,
2006; Bravo Marques, 2009; Leyland-Jones, 2009). Before the
development of HER2-targeted therapies, HER2-positive breast
cancer was associated with poorer patient outcomes when
compared stage for stage with other breast cancer subtypes
(Slamon et al, 1987; Awada et al, 2012). The introduction of
HER2-targeted therapies has resulted in markedly improved
clinical outcomes in both the early- and advanced-stage disease
settings (Cobleigh et al, 1999; Slamon et al, 2001; Piccart-Gebhart
et al, 2005; Romond et al, 2005; Geyer et al, 2006; Slamon et al,
2011; Baselga et al, 2012; Romond et al, 2012; Verma et al, 2012;
Swain et al, 2013), with outcomes in HER2-positive metastatic
breast cancer (MBC) similar to those of patients with HER2-
negative disease (Dawood et al, 2010a). It was recently reported
that the median overall survival (OS) in a cohort of patients with
HER2-positive MBC who were treated with trastuzumab between
1999 and 2005 was 3.5 years from the time of initiation of therapy
in the metastatic setting (Olson et al, 2013). However, despite
improved patient survival times, the majority of patients with
HER2-positive MBC ultimately relapse despite HER2-targeted
treatment (Gajria and Chandarlapaty, 2011).
Biomarkers with the potential to predict decreased sensitivity,
early resistance, or relapse to HER2-directed therapies may include
overexpression of truncated HER2 protein (p95HER2); loss of the
phosphatase and tensin homolog tumour-suppressor gene or
activating mutations in the catalytic or regulatory subunits of
phosphatidylinositol-3 kinase (PI3K), which is associated with
upregulation of the PI3K/AKT/mTOR pathway; and overexpres-
sion of type 1 insulin-like growth factor receptor (Esteva et al,
2010). In patients with HER2-positive MBC, high levels of p95HER2
were found to correlate with decreased progression-free survival
(PFS) and OS (Sperinde et al, 2010) and in patients with HER2-
positive early-stage breast cancer, increased PI3K pathway activity
was associated with a significantly worse OS (Jensen et al, 2012).
Previously identified prognostic indicators in HER2-positive breast
cancer include age, tumour size, axillary lymph node metastases,
lymphovascular invasion, and the level of proliferation cell nuclear
antigen (Liu et al, 2012). Predicting disease outcomes in patients
with MBC is particularly complicated, as this is a biologically
heterogeneous disease (Zidan et al, 2005) associated with variable
clinical behaviour and survival times (Kennecke et al, 2010).
Coupled with an incomplete understanding of the relationship
between clinical characteristics and prognosis in HER2-positive
MBC, the factors that predict outcome or response to HER2-
targeted therapies are mostly exploratory.
Currently, data are limited regarding characteristics of long-
term survivors (LTS) of HER2-positive MBC. RegistHER was a
multicentre, prospective, observational, US-based cohort study of
patients (N¼ 1023) with HER2-positive MBC initiated in 2003.
The objective of this analysis was to identify and describe
homogeneous latent classes labelled as short-term survivors
(STS) and LTS in the registHER study, in relation to demographics,
disease characteristics, and treatment history, using a latent class
modelling (LCM) approach. Additionally, we investigated the
relationship between potential prognostic factors and long-term
survival in this patient population.
MATERIALS AND METHODS
Study design. All of the patients who were recruited to the registHER
study had HER2-positive MBC (newly diagnosed within 6 months) at
the time of enrolment and were recruited to the registHER study from
community and academic settings between December 2003 and
February 2006 (ClinicalTrials.gov, NCT00105456; http://www.
clinicaltrials.gov/ct2/show/NCT00105456). Details of the study
design, recruitment protocols, and study assessments have been
described previously (Brufsky et al, 2011; Rugo et al, 2013).
Previous or planned treatment with trastuzumab or any specific
HER2-targeted therapy was not a requirement for enrolment, and
patients received care in accordance with their physicians’ standard
practice, without study-specified evaluations. Upon enrolment,
treatment history, sites of progressive disease, tumour response,
survival, cardiac safety (grades 3–5), and any adverse events
possibly related to the administration of trastuzumab were
recorded. This information was updated every 3 months thereafter.
In addition, the patients’ demographic information, disease
characteristics, history of breast cancer, history of metabolic
disorders, cardiovascular disease (CVD), and cardiac safety data
were collected. Cardiac safety events were defined using the
Common Terminology Criteria for Adverse Events, v3.0 (National
Cancer Institute, 2006), with selection based on physician opinion.
No prespecified, scheduled assessments for tumour response were
undertaken. Instead, tumour progression was reported by physi-
cians according to their standard assessment schedule, judgment,
and practice. The study was approved by all local institutional
review boards, and all enrolled patients provided informed
consent.
Statistical analysis. Statistical analyses were performed on all
follow-up data for patients participating in registHER as of 15 June
2009 (database lock). The inclusion of data from 83 patients whose
MBC diagnosis was made from 6 to  9 months before enrolment
was permitted, and these data were included in all analyses. Of the
1023 patients in the registHER cohort, 22 were not reported as
receiving any treatment for their MBC during the study, and data
from these patients were therefore excluded from the analysis.
An LCM approach was used to identify one or more distinct
homogeneous groups (latent classes) based on a simultaneous
analysis of three response indicators: tumour response, PFS, and
OS (Goodman, 1974; Vermunt 2009; Ross et al, 2012). The number
of groups was determined by the Bayesian information criterion,
and weights applied to the different indicators were estimated by
maximum likelihood. Each patient was then assigned to the most
likely group based on their posterior membership probabilities.
Latent GOLD (Vermunt and Magidson, 2000) software was used
for the LCM analysis.
Progression-free survival was defined as the time from MBC
diagnosis to the first progression reported by the physicians’
standard practice or death from any cause, whichever occurred
first. Data for patients without disease progression or death as of
the database lock were censored at the time of the last tumour
response evaluation. OS was defined as the time from MBC
diagnosis to the date of death from all causes. Data for patients
without death as of the database lock were censored at the time of
the last follow-up.
Baseline demographic and clinical characteristics were sum-
marised by the two identified latent classes (STS and LTS) and the
entire treated cohort. For continuous data, the number of
observations, mean, s.d., median, minimum, and maximum were
presented. Frequencies and percentages were calculated for
categorical data. Comparability between LTS and STS was
evaluated by the Wilcoxon rank-sum test for continuous data
and by the chi-squared test for categorical data. When appropriate,
95% confidence intervals (CIs) were presented.
Frequencies and percentages of first-line treatment regimens,
best first-line tumour response, and grade 3–5 cardiac adverse
events were calculated. Trastuzumab-based first-line regimens were
defined as patients receivingX21 days of trastuzumab in the first-
line setting. The best first-line overall response was defined as the
best response at any time during first-line treatment. Progression-
free survival and OS were analysed using the Kaplan–Meier
method to estimate median PFS and corresponding 95% CIs for
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Table 1. Baseline demographic and clinical characteristics of STS, LTS, and all treated patients
Variable STS (n¼757) LTS (n¼244)
All treated patients
(N¼1001) P-valuea
Age at enrolment, median years (range) 54 (20–92) 51 (26–82) 53 (20–92) 0.0049
o35 years 39 (5.2) 9 (3.7) 48 (4.8) 0.0117
35–64 years 545 (72.0) 199 (81.6) 744 (74.3)
X65 years 173 (22.9) 36 (14.8) 209 (20.9)
Sex, n (%)
Female 748 (98.8) 243 (99.6) 991 (99.0)
Male 9 (1.2) 1 (0.4) 10 (1.0) 0.2873
Race, n (%)
White 589 (77.8) 204 (83.6) 793 (79.2) 0.1157
Black 104 (13.7) 22 (9.0) 126 (12.6)
Other 64 (8.5) 18 (7.4) 82 (8.2)
BMI, n (%)
o25 kgm 2 254 (33.6) 76 (31.1) 330 (33.0) 0.7163
25 too30 kgm2 236 (31.2) 82 (33.6) 318 (31.8)
X30 kgm 2 267 (35.3) 86 (35.2) 353 (35.3)
ECOG performance status at metastatic diagnosis, n (%)
0–1 329 (43.5) 126 (51.6) 455 (45.5) 0.0791
2þ 48 (6.3) 12 (4.9) 60 (6.0)
Unknown/missing 380 (50.2) 106 (43.4) 486 (48.6)
Serum albumin, n (%)
p3.5gdl1 108 (14.3) 24 (9.8) 132 (13.2) 0.0080
43.5 gdl1 365 (48.2) 145 (59.4) 510 (50.9)
Unknown/missing 284 (37.5) 75 (30.7) 359 (35.9)
ER/PgR status, n (%)
ERþ or PgRþ 385 (50.9) 145 (59.4) 530 (52.9) 0.0075
ER and PgR 348 (46.0) 86 (35.2) 434 (43.4)
Unknown 24 (3.2) 13 (5.3) 37 (3.7)
Site of metastatic disease at diagnosis, n (%)
Any CNS 62 (8.2) 10 (4.1) 72 (7.2) 0.0131
Bone only or boneþbreast 113 (14.9) 35 (14.3) 148 (14.8)
Visceral 466 (61.6) 141 (57.8) 607 (60.6)
Node/local 115 (15.2) 57 (23.4) 172 (17.2)
Other sites 1 (0.1) 1 (0.4) 2 (0.2)
Time to relapse after initial diagnosis, n (%)
p12 months 101 (13.3) 34 (13.9) 135 (13.5) 0.0066
412 months 467 (61.7) 125 (51.2) 592 (59.1)
Stage IV at initial diagnosis (de novo MBC) 189 (25.0) 85 (34.8) 274 (27.4)
History of diabetes, n (%)
Yes 65 (8.6) 13 (5.3) 78 (7.8) 0.0987
No/missing 692 (91.4) 231 (94.7) 923 (92.2)
History of underlying CVD (any)b, n (%)
Angina 2 (0.3) 1 (0.4) 3 (0.3) 0.7174
Arrhythmia 18 (2.4) 4 (1.6) 22 (2.2) 0.4938
Congestive heart failure 13 (1.7) 2 (0.8) 15 (1.5) 0.3156
Hypertension with complications 41 (5.4) 7 (2.9) 48 (4.8) 0.1054
Myocardial infarction 14 (1.8) 5 (2.0) 19 (1.9) 0.8424
Peripheral vascular disease 9 (1.2) 4 (1.6) 13 (1.3) 0.5889
Other underlying cardiac disease 81 (10.7) 18 (7.4) 99 (9.9) 0.1305
History of underlying non-cardiac comorbidities (any), n (%)
Yes 221 (29.2) 58 (23.8) 279 (27.9) 0.1003
No/missing 536 (70.8) 186 (76.2) 722 (72.1)
Abbreviations: BMI¼body mass index; CNS¼ central nervous system; CVD¼ cardiovascular disease; ECOG¼Eastern Cooperative Oncology Group; ER¼oestrogen receptor; LTS¼ long-term
survivors; MBC¼metastatic breast cancer; PgR¼progesterone receptor; STS¼ short-term survivors.
aP-values are from Wilcoxon two-sample test for continuous variables or chi-squared test for categorical variables for short-term vs long-term survivors.
bPatients may be counted in multiple rows.
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each group and overall. A logistic regression analysis on the latent
class variable as a dependent variable with STS as the reference
class was used to evaluate the effect of the following factors: age
(age 35–64 years vs age o35 or age X65 years), race (white vs
non-white), Eastern Cooperative Oncology Group (ECOG)
performance status, serum albumin level, tumour oestrogen
receptor/progesterone receptor (ER/PgR) status, stage of disease
at initial diagnosis, site of metastatic disease (adjusted using a
hierarchical approach, that is, (1) central nervous system (CNS),
(2) bone and/or breast, (3) visceral/other, and (4) node/local), first-
line trastuzumab use, first-line taxane use, history of underlying
CVD, and history of other underlying non-cardiac comorbid
conditions. A sensitivity analysis evaluating the effect of these
factors on OS was also performed using Cox proportional hazards
(PH) analysis.
RESULTS
LCM outcomes. LCM was used to identify one or more distinct
homogeneous LTS group(s) and one or more STS group(s), based
on a simultaneous analysis of complete first-line tumour response,
PFS, and OS. A two-class LCM appeared to be the best model
based on the lowest Bayesian information criterion value. The first
class consisted of 244 (24.4%) of the 1001 patients and included
98.9% of patients (173 out of 175) who experienced a complete
response (CR) as their best overall response. A total of 99.6% (243
out of 244) of patients in this group experienced CR or partial
response (PR)/stable disease (SD) as their best overall response,
and only 50.8% of patients within this class then later experienced
progression following metastatic disease; therefore, this group was
named the ‘LTS latent class’. The second patient group, consisting
of 757 (75.6%) patients, was termed the ‘STS latent class’.
Patient characteristics. Baseline demographic and clinical char-
acteristics for STS and LTS who were followed until death,
withdrawal, or until database lock are shown in Table 1. There was
a statistically significant difference in median age at enrolment
between the two classes (51 years in LTS vs 54 years in STS;
P¼ 0.0049). LTS and STS were similar in terms of the distribution
of obese patients (body mass index X30) and history of diabetes.
The proportion of non-white patients among LTS was lower than
in STS (16.4% vs 22.2%, respectively). LTS were also more likely
to have ERþ or PgRþ disease than STS (59.4% vs 50.9%,
respectively) and a lower rate of underlying CVD (15.6% vs 19.9%,
respectively). More specifically, patients within the LTS latent class
had lower rates of congestive heart failure, hypertension with
complications, arrhythmia, and other underlying cardiac disease
than patients in the STS class (see Table 1), although these
differences were not statistically significant.
Table 2. Treatment patterns before first disease progression
Treatment, n (%) STS (n¼757) LTS (n¼244)
All treated patients
(N¼1001)
First-line trastuzumab-based regimensa n¼613 (81.0) n¼228 (93.4) n¼841 (84.0)
With chemotherapy only 436 (71.1) 130 (57.0) 566 (67.3)
With hormonal therapy only 35 (5.7) 15 (6.6) 50 (5.9)
With chemotherapy and hormonal therapy 93 (15.2) 72 (31.6) 165 (19.6)
Trastuzumab alone 49 (8.0) 11 (4.8) 60 (7.1)
First-line non-trastuzumab regimens n¼144 (19.0) n¼16 (6.6) n¼160 (16.0)
Chemotherapy only 72 (50.0) 7 (43.8) 79 (49.4)
Hormonal therapy only 53 (36.8) 4 (25.0) 57 (35.6)
Chemotherapy and hormonal therapy 8 (5.6) 5 (31.3) 13 (8.1)
o21 days of trastuzumab alone 11 (7.6) 0 11 (6.9)
Duration of trastuzumab in first line
None or o21 days 144 (19.0) 16 (6.6) 160 (16.0)
21 days to 4 months 179 (23.6) 7 (2.9) 186 (18.6)
44–8 months 193 (25.5) 27 (11.1) 220 (22.0)
48–15 months 164 (21.7) 45 (18.4) 209 (20.9)
415 months 77 (10.2) 149 (61.1) 226 (22.6)
First-line treatment with chemotherapy n¼609 (80.4) n¼214 (87.7) n¼823 (82.2)
Taxane 404 (66.3) 169 (79.0) 573 (69.6)
Anthracyclines 38 (6.2) 14 (6.5) 52 (6.3)
Capecitabine 56 (9.2) 21 (9.8) 77 (9.4)
Any lapatinib treatment after MBC diagnosis 172 (22.7%) 38 (15.6%) 210 (21.0%)
Abbreviations: LTS¼ long-term survivors; MBC¼metastatic breast cancer; STS¼ short-term survivors.
aTrastuzumab-based regimens are defined as patients who receivedX21 days of trastuzumab as first-line therapy.
100
90
80
70
60
50
40
30
Pa
tie
nt
s,
 
%
20
10
0
Any CNS Bone and/or
breast
Visceral Node/local
Site of metastatic disease
Other sites
STS
LTS
All treated patients
Figure 1. Site of first disease progression among short-term survivors
(STS), long-term survivors (LTS), and all treated patients. Abbreviation:
CNS¼ central nervous system.
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Although all patients enrolled in the study had stage IV MBC, at
initial diagnosis a greater proportion of the LTS group had stage IV
(de novo) disease than the STS group (34.8% vs 25.0%). The
distribution of site of metastatic disease at diagnosis was similar,
with visceral sites being the most common and CNS being the least
common; however, fewer LTS presented with CNS metastases
compared with STS (4.1% vs 8.2%, respectively), and a greater
proportion of LTS had node/local metastasis vs STS (23.4% vs
15.2%) (see Table 1; Figure 1).
Treatment patterns for MBC before first disease progression.
First-line treatment patterns are defined as the therapeutic agents
that patients received after MBC diagnosis and before first disease
progression, and these may have been given either sequentially or
concurrently. First-line trastuzumab use was higher in LTS (228
out of 244; 93.4%) than in STS (613 out of 757; 81.0%). Among
patients who received chemotherapy as first-line treatment, LTS
were more likely to receive a taxane (169 out of 214; 79.0%)
compared with STS (404 out of 609; 66.3%), while anthracycline
use was similar between these patient groups (6.5% vs 6.2%,
respectively). Among those who received trastuzumab-based first-
line treatment, LTS were more likely to receive hormonal therapy
(15 out of 228; 6.6%) and combined chemotherapy/hormonal
therapy (72 out of 228; 31.6%) compared with STS (35 out of 613;
5.7% and 93 out of 613; 15.2%, respectively) and less likely to
receive chemotherapy and trastuzumab alone (Table 2).
Clinical outcomes. Before database lock, 15.2% of LTS had died
compared with 65.3% of STS (Table 3). On average, LTS survived
significantly longer without progressive disease than STS
(median PFS, 37.2 months (95% CI: 32.9–40.5) vs 7.3 months
(95% CI: 6.8–8.0) (Figure 2A). The median OS in STS was 27.2
months (95% CI: 25.4–29.3) but was non-estimable (NE) in LTS
because the median OS was not reached (Figure 2B). The
proportion of patients achieving physician-assessed first-line CR
was much higher in LTS than in STS (70.9% vs 0.3%, respectively),
and as a consequence, the proportion of patients achieving PR/SD
was lower in LTS than in STS (28.7% vs 68.7%, respectively)
(see Table 3). The time between MBC diagnosis and achieving
CR/PR/SD was longer in LTS, with 52.7% of LTS achieving
CR/PR/SD ino6 months compared with 91.0% of STS (see
Table 3). The proportion of patients with disease progression was
lower for LTS than for STS (50.8% vs 91.4% respectively). Although
the distribution of metastasis to different body sites was similar
between the two patient classes, the incidence of any CNS event
was lower among LTS than among STS (18.9% vs 43.3%,
respectively).
Cardiac safety outcomes. The incidence of any cardiac safety
event (grades X3) was slightly lower in LTS (4.1%) than in STS
(7.1%) (Supplementary Table 1). Left ventricular dysfunction was
the most prevalent cardiac adverse event in both LTS (2.0%) and
STS (2.0%).
Factors associated with short-term survival. Prognostic factors
associated with the probability of short-term survival as an
outcome were assessed using logistic regression analysis
(Figure 3). Factors significantly associated with increased odds
that a patient was classified as STS were older age at enrolment
(X65 years), non-white race, serum albumin (p3.5 g dl 1),
recurrent MBC, and metastasis to the CNS. Conversely, factors
associated with increased odds that a patient was classified as LTS
included ERþ or PgRþ disease, metastasis to bone and/or
breast or node/local sites (vs visceral/other metastasis), first-line
Table 3. Clinical outcomes stratified by survivor group
Parameter Category/statistics STS (n¼757) LTS (n¼244)
All treated patients
(N¼1001)
Number of deaths n (%) 494 (65.3) 37 (15.2) 531 (53.0)
Due to progression 458 (92.7) 34 (91.9) 492 (92.7)
Other 36 (7.3) 3 (8.1) 39 (7.3)
PFS since metastatic diagnosis (months) Median (95% CI) 7.3 (6.8–8.0) 37.2 (32.9–40.5) 10.2 (9.4–11.0)
Number of patients with first progression of disease n (%) 692 (91.4) 124 (50.8) 816 (81.5)
OS since metastatic diagnosis (months) Median (95% CI) 27.2 (25.4–29.3) NE 35.9 (32.8–39.5)
Best first-line response, n (%)
CR 2 (0.3) 173 (70.9) 175 (17.5)
PR/SD 520 (68.7) 70 (28.7) 590 (58.9)
Unable to evaluate 20 (2.6) 1 (0.4) 21 (2.1)
No assessment 215 (28.4) 0 215 (21.5)
Time between CR and MBC diagnosis,n (%) n¼2 n¼173 n¼175
p6 months 2 (100.0) 69 (39.9) 71 (40.6)
6 top12 months 0 52 (30.1) 52 (29.7)
12 top18 months 0 22 (12.7) 22 (12.6)
18 top24 months 0 14 (8.1) 14 (8.0)
424 months 0 16 (9.2) 16 (9.1)
Time between CR/PR/SD and MBC diagnosis, n (%) n¼522 n¼243 n¼765
p6 months 475 (91.0) 128 (52.7) 603 (78.8)
6 top12 months 45 (8.6) 59 (24.3) 104 (13.6)
12 top18 months 2 (0.4) 23 (9.5) 25 (3.3)
18 top24 months 0 14 (5.8) 14 (1.8)
424 months 0 19 (7.8) 19 (2.5)
Abbreviations: CI¼ confidence interval; CR¼ complete response; LTS¼ long-term survivors; MBC¼metastatic breast cancer; NE¼non-estimable; OS¼overall survival; PFS¼progression-free
survival; PR, partial response; SD¼ stable disease; STS¼ short-term survivors.
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trastuzumab use, and first-line taxane use. Prognostic factors
associated with OS in all the treated patients were also assessed
using Cox PH analysis (Figure 4). All of the factors that were
associated with increased odds that a patient fell in the STS class in
the logistic regression analysis were also associated with an
increased risk of mortality in the Cox PH analysis. However, in
contrast to the logistic regression analysis, in the Cox PH model, an
ECOG performance status of 2þ was associated with an increased
risk of mortality (hazard ratio (HR), 2.022, 95% CI: 1.434–2.851).
DISCUSSION
Prolonged, relapse-free survival has previously been documented
in a small subset (B2–3%) of MBC patients, regardless of HER2
status (Greenberg et al, 1996; Kobayashi et al, 2012); however,
there is a paucity of data characterising long-term survival within
the HER2-positive MBC population. In our study, baseline
demographic and clinical characteristics in the LTS and STS
patient cohorts classified by LCM were generally similar, although
there were notable exceptions, suggesting that biological differences
exist between these groups. For example, LTS were less likely to
have ER/PgR-negative disease, which is consistent with previous
studies demonstrating that patients with HER2-positive, ER/PgR-
negative tumours have a poor prognosis (Carey et al, 2006;
Largillier et al, 2008; Onitilo et al, 2009). However, this is in
contrast with recent accumulating evidence that ER/PgR-positivity
may confer a risk of late recurrence, which may not be captured
within the follow-up time period of standard clinical trials.
Another difference was the lower proportion of non-white patients
in the LTS compared with the STS. Although socioeconomic
factors and access to care may contribute to racial differences in the
stage of breast cancer at diagnosis and subsequent treatment,
underlying biological differences in breast cancer phenotypes
between African-American and European-American women,
irrespective of HER2 status, have previously been documented
(Amend et al, 2006). Black race has previously been associated
with poor prognosis and lower survival rates (Ooi et al, 2011;
Sparano et al, 2012; Rugo et al, 2013), and this difference in
survival persists following adjustment for socioeconomic factors
(Newman, 2005; Du et al, 2011). In addition, a greater proportion
of the LTS had stage IV disease at initial diagnosis (i.e., de novo
metastatic disease) compared with STS and may be due to effects of
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Figure 3. Logistic regression analysis examining prognostic factors associated with short-term survivors (STS). Abbreviations: CI¼ confidence
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previous drug exposure. This is consistent with results from a
separate analysis from registHER comparing outcomes in patients
with de novo vs recurrent MBC at initial diagnosis, which
demonstrated that patients with de novo MBC had longer median
OS than patients with recurrent MBC (Yardley et al, 2014).
Analysis of treatment patterns in LTS and STS found that LTS
were more likely to have undergone first-line trastuzumab
treatment (93.4% vs 81.0%, respectively) and were more likely to
have been treated with a taxane (79.0% vs 66.3%, respectively). In
addition, LTS were twice as likely to have been treated with a
combination of trastuzumab, chemotherapy, and hormones as STS
(31.6% vs 15.2%). It is unclear whether these differences result
from treatment effects or are simply due to ‘treatment selection
bias’ due to the observational non-randomised nature of this study.
Additionally, as biological factors may influence both outcome and
physician treatment choices, it is difficult to directly correlate
treatment patterns with survival.
When examining outcomes, the proportion of patients achiev-
ing a first-line CR was significantly higher in LTS than in STS
(70.9% (173 out of 244) vs 0.3% (2 out of 757), respectively).
Additionally, the time between MBC diagnosis and achieving a
response of SD or better was shorter in STS, suggesting that some
intrinsic factors may result in more responsive disease that was not
durable, with more rapid development of resistance; however, the
exact factors are currently unknown. Likewise, PFS was signifi-
cantly longer in LTS compared with STS (median PFS 37.2 months
(95% CI: 32.9–40.5) vs 7.3 months (95% CI: 6.8–8.0), respectively).
It has previously been suggested that achieving an initial CR is a
prerequisite for long-term disease-free status following MBC
diagnosis (Greenberg et al, 1996). In our analysis, 98.9% (173
out of 175) of the patients who achieved a CR following first-line
treatment were in the LTS group, suggesting that in HER2-positive
MBC CR to first-line therapy is strongly associated with survival
and may partially account for the noted disparities in PFS between
these two groups.
Prognostic factors associated with STS in our analysis were
older age at enrolment (X65 years), non-white race, serum
albumin p3.5 g dl 1, recurrent disease, and metastasis to
the CNS. This is consistent with multiple previous reports in
both HER2-positive and in unselected patients (Lis et al, 2003;
Brunetto et al, 2010; Dawood et al, 2010b; Ooi et al, 2011; Kaufman
et al, 2012; Sparano et al, 2012), including a recent retrospective
analysis of 1038 women noting that age at initial diagnosis ofo50
years and hormonal receptor-positive status were the most relevant
prognostic factors for longer survival, while the development of
CNS, multiple, and/or hepatic sites of metastasis were prognostic
for worse survival (Largillier et al, 2008).
In this study, an LCM approach was used to identify the two
homogeneous survival groups labelled as STS and LTS, rather than
selecting a survival time point to define them (Yardley et al, 2012).
The use of LCM in this study enabled the identification of two
groups that are biologically distinct in terms of clinical features
(ER/PgR status), age, race, and also disease response (longer PFS
and higher CR rates). LCM allows for the identification of distinct
long-term and short-term survival sub-populations without the use
of an arbitrary cutoff time point. In addition, LCM utilises
information from multiple response variables, and right censoring
is handled in a statistically appropriate way, because posterior
membership probabilities are estimated for all subjects, regardless
of the number of months of follow-up. Patients were assigned to
the latent class (either STS or LTS) in which they have the highest
posterior membership probability, and there is uncertainty
associated with this unless the membership probability is 1.
Although this uncertainty can be modelled (Vermunt, 2010), for
simplicity, the latent class assignment was assumed to contain no
error; therefore it is important to interpret the results with some
caution.
In addition to limitations of the LCM analyses, further study
limitations may have included ‘confounding effects’ resulting from
the non-randomised and observational nature of the registHER
study cohort. However, within each class the observed variables are
statistically independent. This analysis may also have residual
confounding owing to its inability to control for patient treatment
compliance and previous treatment patterns, tumour size, and New
York Heart Association Functional Classification. In addition,
because patients could potentially have had a diagnosis of MBC for
up to 9 months before enrolment, there is the possibility of
selection bias for patients with a longer OS. The median OS for all
treated patients in this study was 35.9 months; however, it has
recently been reported that the median OS of HER2-positive MBC
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Figure 4. Cox proportional hazards model for overall survival. Abbreviations: CI¼ confidence interval; CNS¼ central nervous system;
CVD¼ cardiovascular disease; ECOG¼Eastern Cooperative Oncology Group; ER¼oestrogen receptor; HR¼hazard ratio; PgR¼progesterone
receptor.
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now exceeds 3 years (Olson et al, 2013), suggesting that patients
with a longer OS have not been selected for within this population.
Currently, approaches to managing MBC focus on individualis-
ing treatment to best target the patient’s as well as the tumour’s
clinical and molecular characteristics. Physician’s awareness
regarding the variability in the prognosis for patients with
stage IV disease is crucial in making optimal treatment
recommendations.
In addition to guiding treatment decisions, a better under-
standing of prognostic factors in MBC, particularly in the
increasingly smaller subgroup of patients with HER2-positive
disease, may lead to improved clinical trial design to evaluate new
therapeutic agents and/or concurrent and sequential treatment
combinations as well as dual HER2-targeting strategies. As the
outcomes for HER2-positive MBC continue to improve, long-term
follow-up of these patients to capture prospective treatment
patterns, such as in registHER and the subsequent SystHERs
registry, are required to develop prognostic models for identifica-
tion of patients who may expect to experience long-term disease
control and potentially curative outcomes.
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